 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lasa Supergener Standalone September 2023 Net Sales at Rs 24.30 crore, down 27.8% Y-o-Y

Lasa Supergenerics  announced that the 8th Annual General Meeting (AGM) of the company will be held on 27 September 2023.

Lasa Supergenerics  AGM scheduled

Lasa Supergener Standalone March 2023 Net Sales at Rs 35.32 crore, down 31.03% Y-o-Y

Lasa Supergener Standalone June 2022 Net Sales at Rs 28.88 crore, down 19.93% Y-o-Y

Lasa Supergenerics Ltd. engages in the manufacture of veterinary preparations. It offers veterinary application programming interface products, animal feed ingredients, and reagents for therapeutic use. Its products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Triclabendazole, Rafoxanide, and Ornidazole. The company was founded on March 11, 2016 and is headquartered in Mumbai, India.

Watchers	1
52-Wk Low	17.10
52-Wk High	37.70

Market Cap	1.31B
Volume (M)	179,904.00
52-Wk High	37.70
52-Wk Low	17.10

Current Price	26.05
Prev Close	26.25
Open	26.10
Dividend Yield	0.00%
50-Day Moving Average	26.23
Beta	0.20
Avg. Volume	29,765.00
PE Ratio	-4.84

52-Week High	37.70
52-Week Low	17.10
Market Capitalization	1.31B
EPS	-5.42
Price to Book	1.16
Revenue Per Employee	13.7M
Enterprise Value/EBITDA	18.63

LASA.NSE Lasa Supergenerics Ltd.

About

Feed

News

Fundamentals